Generic Name and Formulations:
Anthralin 1%; crm, contains salicylic and ascorbic acid.
Indications for DRITHO-CREME:
Quiescent or chronic psoriasis.
Initially apply once daily (5–10 minutes contact time) for at least one week; may increase contact time to 20–30 minutes before washing off. Treat until skin is entirely clear. Individualize. For skin: use sparingly. For scalp: wash and rinse hair.
Acute psoriatic eruptions.
Renal disease. Avoid eyes, mucous membranes, folds and creases of the skin. Apply cautiously on intertriginous skin areas. Restrict application to psoriatic lesions. Discontinue if sensitization or excessive irritation develops. May stain fabrics; avoid. Pregnancy (Cat.C). Nursing mothers.
Possible contact allergic reactions, severe irritation, discolored hair or fingernails.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML